Lab21 adds Susan Lowther as CFO
This article was originally published in Clinica
Executive Summary
UK personalised medicine firm Lab21 has made Susan Lowther its CFO. Ms Lowther has previously held senior management positions at biopharma firms BioWisdom, RiboTargets and Lonza Biologics, biotech company Celltech and plant biotechnology expert Monsanto. She replaces Maddy Kennedy, who has become director at a consulting business focussed on supporting high-tech, entrepreneurial businesses through growth, funding and mergers and acquisitions called CFO4Growth. Cambridge-based Lab21 specialises in immunodiagnostic kits and reagents for the infectious disease and blood banking markets.
You may also be interested in...
Alere aided by professional diagnostics sales in fourth quarter
Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.
Integra and Stout to work on expandable interbody device
Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.
Gen-Probe eyes portfolio expansion to help boost molecular diagnostics credentials
Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals